ACCESS Newswire
17 May 2022, 15:43 GMT+10
SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) (www.internationalstemcell.com) ('ISCO' or 'the Company'), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and financial results for the three months ended March 31, 2022.
'I would like to highlight the fact that our business units are steadily growing based on the first quarter reported results and the evaluation portion of our Phase 1 clinical trial is progressing successfully as well.' stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO. ' stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO.
Q1 2022 Financial Highlights:
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
For more information, please visit http://internationalstemcell.com/ or contact: [email protected]
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments and company achievements, expected clinical studies (including results and ongoing evaluation of the phase 1 clinical trial), and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,') should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except share and par value data)
International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
Contacts:
International Stem Cell Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email: [email protected]
SOURCE: International Stem Cell Corporation
Get a daily dose of St Louis Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to St Louis Star.
More InformationWARSAW, Poland: Poland held a second round of voting in its presidential election on Sunday, but exit polls show the race is too close...
WEST JERUSALEM, Israel: Israeli forces stopped a boat heading to Gaza and detained Greta Thunberg and other activists on board early...
MELBOURNE, Australia: A second embryo mix-up in just two months has pushed one of Australia's largest IVF providers back into the spotlight,...
WASHINGTON, D.C. A public fight between U.S. President Donald Trump and billionaire Elon Musk has taken over social media, especially...
DERA BAJWA, Pakistan: Amir Ali, a 21-year-old man from Pakistan, dreamed of going to Europe for a better life. He was promised a visa...
TOKYO, Japan: Japan's hopes for a foothold in commercial lunar exploration suffered a second blow this week after Tokyo-based startup...
WASHINGTON, D.C.: A boom in U.S. solar energy installations may be running out of steam as shifting federal priorities, new tariffs,...
NEW YORK CITY, New York: Oil prices remained steady on June 9 as investors looked ahead to the outcome of the U.S.-China trade talks...
CHANDRAPUR/SOLAPUR (India): As India doubles down on coal to fuel its growing energy needs, an invisible crisis is surfacing: the country...
NEW YORK, New York - U.S. stock markets rose Tuesday as investors and traders anticipated a positive outcome from ongoing trade talks...
BEIJING/WASHINGTON, D.C.: In a rare move aimed at easing mounting supply chain pressure, China has issued temporary export licenses...
BERN, Switzerland: UBS faces a sweeping new capital requirement from the Swiss government, which this week proposed changes that could...